Ozempic linked to cheek hollowing and sagging: doctors warn

As GLP‑1 weight-loss drugs like Ozempic, Wegovy and Mounjaro become more widely used, plastic surgeons are reporting a rise in a specific facial change that patients notice only after shedding weight quickly: loss of fullness at the temples. That change, known clinically as temporal hollowing, can alter perceived age and expression—and prompt people to seek corrective procedures that carry real medical risks.

What is temporal hollowing?

Temporal hollowing describes a visible indentation or loss of volume in the area between the eye and the hairline. It often appears after rapid weight loss because subcutaneous fat in that zone diminishes faster than in other parts of the face.

Patients typically complain they look gaunt, tired, or unexpectedly older, though they may not immediately identify the temples as the cause. Surgeons say the change can be subtle but striking because the temples play a key role in facial balance.

Why the temples matter

Facial harmony depends on volume in several regions; the temples are one of those silent contributors. When temple fullness is reduced, the midface and eyes can appear more hollowed, changing overall expression and giving a prematurely aged look.

Dr. Terry Dubrow, a plastic surgeon in Beverly Hills, notes that temple volume helps keep a face looking rested and proportionate. Another surgeon, Dr. Krishna Vyas, warns that restoring volume without a careful plan can create new aesthetic problems if done indiscriminately.

Treatments, benefits and risks

Treatment approaches range from minimally invasive fillers to surgical fat grafting. Each option has trade-offs in longevity, recovery and safety.

• Dermal fillers — Quick outpatient procedures that restore volume immediately; results are temporary and reversible but require precise technique. The temple is a high‑risk area because of nearby blood vessels; improper injection can cause serious complications, including tissue loss or blindness.
• Fat transfer — Uses the patient’s own fat to replenish the temples; results can last longer but involve surgical harvesting and variable fat survival rates.
• Surgical implants or structural facial procedures — Considered in select cases but less commonly used solely for temple hollowing.

Doctors stress the importance of seeking licensed, experienced practitioners. Because of the vascular anatomy of the temple, treatment should never be performed by unqualified providers or in nonmedical settings.

How to reduce the chance of temporal hollowing

Prevention focuses on the pace of weight loss and on medical supervision. When GLP‑1 medications are introduced and titrated according to a prescriber’s plan, many patients avoid abrupt facial volume changes.

Surgeons advise that rapid, unsupervised dosing or purchasing drugs through informal channels increases the likelihood of dramatic weight loss and subsequent facial changes. Dubrow and others recommend following a clinician’s instructions and discussing aesthetic concerns with your prescribing doctor before starting treatment.

Expert takeaways

In short:

• Temporal hollowing is an increasingly observed outcome of fast weight loss on GLP‑1 drugs.
• Temples are anatomically complex; interventions carry measurable risks, including vascular injury.
• Prevention through gradual weight loss and proper medical guidance is preferable to corrective procedures.
• If treatment is needed, choose a board‑certified provider experienced with temple anatomy.

As GLP‑1 treatments remain a common tool against obesity, both patients and clinicians are adapting to new downstream effects—cosmetic, medical and psychological. Understanding the risks and options for temple volume loss can help people make safer, more informed choices about their treatment and aesthetic care.